RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Caladrius Biosciences - Stock

Caladrius Biosciences Net Income 2024

Caladrius Biosciences Net Income

-22.86 M USD

Ticker

CLBS

ISIN

US1280582032

WKN

A2APJW

In 2024, Caladrius Biosciences's profit amounted to -22.86 M USD, a 2.78% increase from the -22.25 M USD profit recorded in the previous year.

The Caladrius Biosciences Net Income history

YEARNET INCOME (undefined USD)
2026e-20.85
2025e-21.62
2024e-22.86
2023e-22.25
2022-54.23
2021-27.47
2020-8.15
2019-19.36
2018-16.17
201722.98
2016-32.66
2015-80.89
2014-54.87
2013-38.98
2012-53.77
2011-47.13
2010-23.31
2009-26.17
2008-9.24
2007-10.45
2006-6.05
2005-1.75
2004-1.75
2003-1.04

Caladrius Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Caladrius Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Caladrius Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Caladrius Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Caladrius Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Caladrius Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Caladrius Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Caladrius Biosciences’s growth potential.

Caladrius Biosciences Revenue, Profit, and EBIT History

DateCaladrius Biosciences RevenueCaladrius Biosciences EBITCaladrius Biosciences Net Income
2026e13.5 M undefined-29.6 M undefined-20.85 M undefined
2025e9 M undefined-32.83 M undefined-21.62 M undefined
2024e6.12 M undefined-37.14 M undefined-22.86 M undefined
2023e4.08 M undefined-32.73 M undefined-22.25 M undefined
20220 undefined-57.6 M undefined-54.23 M undefined
20210 undefined-29.05 M undefined-27.47 M undefined
20200 undefined-19.15 M undefined-8.15 M undefined
20190 undefined-20.09 M undefined-19.36 M undefined
20180 undefined-16.99 M undefined-16.17 M undefined
20170 undefined-27.59 M undefined22.98 M undefined
20160 undefined-29.5 M undefined-32.66 M undefined
201522.49 M undefined-51.58 M undefined-80.89 M undefined
201417.94 M undefined-57.74 M undefined-54.87 M undefined
201314.67 M undefined-36.81 M undefined-38.98 M undefined
201214.33 M undefined-30.39 M undefined-53.77 M undefined
201110.05 M undefined-34 M undefined-47.13 M undefined
201069.82 M undefined-18.32 M undefined-23.31 M undefined
200911.57 M undefined-25.87 M undefined-26.17 M undefined
200880,000 undefined-9.23 M undefined-9.24 M undefined
2007230,000 undefined-10.44 M undefined-10.45 M undefined
200650,000 undefined-4.69 M undefined-6.05 M undefined
200540,000 undefined-1.6 M undefined-1.75 M undefined
200450,000 undefined-1.47 M undefined-1.75 M undefined
200370,000 undefined-890,000 undefined-1.04 M undefined

Caladrius Biosciences stock margins

The Caladrius Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Caladrius Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Caladrius Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Caladrius Biosciences's sales revenue. A higher gross margin percentage indicates that the Caladrius Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Caladrius Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Caladrius Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Caladrius Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Caladrius Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Caladrius Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Caladrius Biosciences Margin History

Caladrius Biosciences Gross marginCaladrius Biosciences Profit marginCaladrius Biosciences EBIT marginCaladrius Biosciences Profit margin
2026e9.56 %-219.29 %-154.42 %
2025e9.56 %-364.78 %-240.19 %
2024e9.56 %-606.8 %-373.6 %
2023e9.56 %-802.27 %-545.25 %
20229.56 %0 %0 %
20219.56 %0 %0 %
20209.56 %0 %0 %
20199.56 %0 %0 %
20189.56 %0 %0 %
20179.56 %0 %0 %
20169.56 %0 %0 %
20159.56 %-229.35 %-359.67 %
201411.59 %-321.85 %-305.85 %
201310.5 %-250.92 %-265.71 %
201215.35 %-212.07 %-375.23 %
201112.24 %-338.31 %-468.96 %
201028.86 %-26.24 %-33.39 %
200916.08 %-223.6 %-226.19 %
200862.5 %-11,537.5 %-11,550 %
200791.3 %-4,539.13 %-4,543.48 %
200640 %-9,380 %-12,100 %
200525 %-4,000 %-4,375 %
200440 %-2,940 %-3,500 %
200328.57 %-1,271.43 %-1,485.71 %

Caladrius Biosciences Aktienanalyse

What does Caladrius Biosciences do?

Caladrius Biosciences Inc was founded in 1980 as a pharmaceutical biotechnology company and is headquartered in Basking Ridge, New Jersey. The company focuses on developing cellular therapies for the treatment of serious diseases. Caladrius Biosciences aims to improve the lives of patients with unmet medical needs by developing novel and innovative therapies based on neuroscientific, immunological, and regenerative approaches. The business model of Caladrius Biosciences is based on researching and developing products that focus on the needs of patients. The goal is to concentrate on innovative and groundbreaking therapies that can treat diseases that have not been adequately treated before. The company has developed a portfolio of groundbreaking products based on stem cell, immune, and regenerative therapies. Caladrius Biosciences has three different business areas: - The first business area is its subsidiary PCT, LLC, which offers clinical manufacturing services in the field of clinical cell therapies. The subsidiary provides a scalable platform for the production of individual cell-based therapies. - The second business area is conducting clinical trials, including in the field of cardiovascular diseases. Caladrius Biosciences collaborates closely with clinics, doctors, and other professionals to demonstrate the potential of its own products through clinical studies. - The third area is the development of innovative therapies for diseases that previously could not be treated. The company is working on regenerative, immunological, and stem cell therapies. Caladrius has various products in development based on novel technologies, such as stem cell therapy. The company focuses on cardiovascular diseases, autoimmune diseases, and cancer. One of the flagship products of the company is CLBS201, which is a stem cell treatment for coronary heart disease. It is an autologous cell-based product derived from a patient's bone marrow and is used in combination with angioplasty, a minimally invasive surgical procedure to widen narrowed or blocked blood vessels. In summary, Caladrius Biosciences Inc is a leading biopharmaceutical company that focuses on developing innovative stem cell and immune therapies for the treatment of serious diseases. The company prioritizes the needs of patients and has established a unique position in the regenerative and cell-based therapy industry. Caladrius Biosciences pursues a long-term and sustainable growth model by relying on innovative technologies and clinical trials to continue developing groundbreaking products. In short, Caladrius Biosciences tirelessly works to improve the lives of people and cure diseases that were previously considered incurable. Caladrius Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Caladrius Biosciences's Profit Margins

The profit margins of Caladrius Biosciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Caladrius Biosciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Caladrius Biosciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Caladrius Biosciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Caladrius Biosciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Caladrius Biosciences Stock

How much profit has Caladrius Biosciences made this year?

Caladrius Biosciences has made -22.86 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 2.78% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Caladrius Biosciences publish its earnings?

Caladrius Biosciences publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Caladrius Biosciences?

The profits of Caladrius Biosciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Caladrius Biosciences?

You can learn more about the earnings of Caladrius Biosciences by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Caladrius Biosciences pay?

Over the past 12 months, Caladrius Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Caladrius Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Caladrius Biosciences?

The current dividend yield of Caladrius Biosciences is .

When does Caladrius Biosciences pay dividends?

Caladrius Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Caladrius Biosciences?

Caladrius Biosciences paid dividends every year for the past 0 years.

What is the dividend of Caladrius Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Caladrius Biosciences located?

Caladrius Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Caladrius Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Caladrius Biosciences from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Caladrius Biosciences pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Caladrius Biosciences in the year 2023?

In the year 2023, Caladrius Biosciences distributed 0 USD as dividends.

In which currency does Caladrius Biosciences pay out the dividend?

The dividends of Caladrius Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Caladrius Biosciences

Our stock analysis for Caladrius Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Caladrius Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.